Cibus, Inc. (NASDAQ:CBUS) Short Interest Update

Cibus, Inc. (NASDAQ:CBUS) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totaling 3,427,664 shares, a growth of 66.8% from the March 15th total of 2,055,342 shares. Currently, 7.2% of the shares of the company are sold short. Based on an average daily volume of 880,176 shares, the short-interest ratio is currently 3.9 days.

Cibus Price Performance

Shares of CBUS stock traded up $0.08 during midday trading on Wednesday, reaching $1.50. 93,733 shares of the company were exchanged, compared to its average volume of 583,373. Cibus has a 12 month low of $1.09 and a 12 month high of $4.19. The company has a market cap of $103.45 million, a P/E ratio of -0.50 and a beta of 1.93. The company’s 50 day moving average price is $2.68 and its two-hundred day moving average price is $1.98. The company has a debt-to-equity ratio of 1.37, a quick ratio of 0.72 and a current ratio of 0.72.

Cibus (NASDAQ:CBUS) last released its quarterly earnings results on Tuesday, March 17th. The company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.01. Cibus had a negative net margin of 3,492.30% and a negative return on equity of 174.58%. The company had revenue of $1.06 million for the quarter, compared to the consensus estimate of $1.64 million. On average, sell-side analysts expect that Cibus will post -2.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Cibus in a research report on Wednesday, January 21st. Jefferies Financial Group boosted their price target on shares of Cibus from $1.90 to $3.00 and gave the stock a “hold” rating in a research report on Wednesday, March 25th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $9.00.

Institutional Trading of Cibus

A number of hedge funds and other institutional investors have recently made changes to their positions in CBUS. Rockland Trust Co. bought a new stake in shares of Cibus in the 3rd quarter worth approximately $26,000. PACK Private Wealth LLC bought a new stake in shares of Cibus in the 4th quarter worth approximately $27,000. Qube Research & Technologies Ltd bought a new stake in shares of Cibus in the 2nd quarter worth approximately $39,000. Squarepoint Ops LLC bought a new stake in shares of Cibus in the 3rd quarter worth approximately $62,000. Finally, AQR Capital Management LLC bought a new stake in shares of Cibus in the 1st quarter worth approximately $73,000. 33.81% of the stock is currently owned by institutional investors.

Cibus Company Profile

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.